Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)
The article presents epidemiological data on the high prevalence of hypertension and dyslipidemia comorbidity in the general population, as well as shows the leading role of these key cardiovascular risk factors in the development of cardiovascular events. At the same time, within the primary preven...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2022-12-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/5285 |
| _version_ | 1797856586845126656 |
|---|---|
| author | V. V. Kashtalap |
| author_facet | V. V. Kashtalap |
| author_sort | V. V. Kashtalap |
| collection | DOAJ |
| description | The article presents epidemiological data on the high prevalence of hypertension and dyslipidemia comorbidity in the general population, as well as shows the leading role of these key cardiovascular risk factors in the development of cardiovascular events. At the same time, within the primary prevention, the adherence of patients to the lipid-lowering therapy remains low. Fixed-dose combinations (Lipertans) based on antihypertensive (amlodipine, perindopril) and lipid-lowering drugs (atorvastatin) can significantly increase the effectiveness of therapy. |
| first_indexed | 2024-04-09T20:43:55Z |
| format | Article |
| id | doaj.art-ebbc5dae6add4248b9c54caddfba3e05 |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2024-04-09T20:43:55Z |
| publishDate | 2022-12-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-ebbc5dae6add4248b9c54caddfba3e052023-03-29T21:23:42Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202022-12-01271110.15829/1560-4071-2022-52853713Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)V. V. Kashtalap0Research Institute for Complex Issues of Cardiovascular DiseasesThe article presents epidemiological data on the high prevalence of hypertension and dyslipidemia comorbidity in the general population, as well as shows the leading role of these key cardiovascular risk factors in the development of cardiovascular events. At the same time, within the primary prevention, the adherence of patients to the lipid-lowering therapy remains low. Fixed-dose combinations (Lipertans) based on antihypertensive (amlodipine, perindopril) and lipid-lowering drugs (atorvastatin) can significantly increase the effectiveness of therapy.https://russjcardiol.elpub.ru/jour/article/view/5285hypertensiondyslipidemiacardiovascular riskcomorbidityfixeddose combinationspolypills |
| spellingShingle | V. V. Kashtalap Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation) Российский кардиологический журнал hypertension dyslipidemia cardiovascular risk comorbidity fixeddose combinations polypills |
| title | Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation) |
| title_full | Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation) |
| title_fullStr | Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation) |
| title_full_unstemmed | Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation) |
| title_short | Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation) |
| title_sort | therapy for hypertension and dyslipidemia potential of lipertans on the example of a clinical observation |
| topic | hypertension dyslipidemia cardiovascular risk comorbidity fixeddose combinations polypills |
| url | https://russjcardiol.elpub.ru/jour/article/view/5285 |
| work_keys_str_mv | AT vvkashtalap therapyforhypertensionanddyslipidemiapotentialoflipertansontheexampleofaclinicalobservation |